CM
ALXN

Crestline Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Crestline Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-41,179
Closed -$5.11M – 261
2018
Q2 		$5.11M Buy
41,179
+13,666
+50% +$1.6M 0.54% 20
2018
Q1 		$3.07M Sell
27,513
-8,460
-24% -$1.01M 0.38% 34
2017
Q4 		$4.3M Buy
+35,973
New +$4.38M 0.44% 18
2017
Q1 		– Sell
-1,945
Closed -$238K – 140
2016
Q4 		$238K Buy
+1,945
New +$238K 0.06% 77

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Crestline Management's ALXN Position: Q3 2018 in Review

Crestline Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 41,179 shares — an estimated $5.11M sold.

Crestline Management first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $5.11M in Q2 2018. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Crestline Management reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 41,179 Alexion Pharmaceuticals shares in Q3 2018, an estimated $5.11M.
  • Crestline Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Crestline Management's Alexion Pharmaceuticals position peaked at $5.11M in Q2 2018.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.